Merck & Co. Partners with Dragonfly on NK-Based Cancer Immunotherapies

Merck & Co. plans to develop new solid tumor cancer immunotherapies using Dragonfly Therapeutics’ Tri-specific NK cell Engagement...

Dragonfly Founders to Lead Disruptors Conversation at Boston Biotech

Every life sciences startup aims to shake up and challenge the status quo. But which Boston companies are taking the most radical...

Dragonfly and Merck Strike $695 Million Deal for Solid Tumors

Waltham, Mass.-based Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck. Merck will license...

Celgene bags option on NK cell-based blood cancer assets

Celgene has landed an option on four natural killer (NK) cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics. The...

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

by John Carroll Editor & Founder of ENDPOINTS Over the last 15 years I’ve had the chance to help select about 200 private biotechs for...

Dragonfly, Tyler Jacks’s Disney-Backed Startup, Gets $33M in Celgene Deal

Dragonfly Therapeutics, a stealthy startup formed by well-known cancer researchers on both coasts and backed by a high-powered group of...